ENVB vs. MRKR, NXTC, AYTU, CLDI, BCTX, CLRB, BGXX, BCDA, INAB, and HOTH
Should you be buying Enveric Biosciences stock or one of its competitors? The main competitors of Enveric Biosciences include Marker Therapeutics (MRKR), NextCure (NXTC), Aytu BioPharma (AYTU), Calidi Biotherapeutics (CLDI), BriaCell Therapeutics (BCTX), Cellectar Biosciences (CLRB), Bright Green (BGXX), BioCardia (BCDA), IN8bio (INAB), and Hoth Therapeutics (HOTH). These companies are all part of the "pharmaceutical products" industry.
Enveric Biosciences vs.
Enveric Biosciences (NASDAQ:ENVB) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings, risk and community ranking.
Enveric Biosciences has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Comparatively, Marker Therapeutics has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500.
In the previous week, Marker Therapeutics had 5 more articles in the media than Enveric Biosciences. MarketBeat recorded 6 mentions for Marker Therapeutics and 1 mentions for Enveric Biosciences. Enveric Biosciences' average media sentiment score of 1.00 beat Marker Therapeutics' score of 0.00 indicating that Enveric Biosciences is being referred to more favorably in the media.
Marker Therapeutics received 69 more outperform votes than Enveric Biosciences when rated by MarketBeat users. Likewise, 64.66% of users gave Marker Therapeutics an outperform vote while only 60.00% of users gave Enveric Biosciences an outperform vote.
Marker Therapeutics has higher revenue and earnings than Enveric Biosciences. Marker Therapeutics is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.
Enveric Biosciences presently has a consensus target price of $10.00, indicating a potential upside of 709.72%. Marker Therapeutics has a consensus target price of $13.17, indicating a potential upside of 1,096.97%. Given Marker Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Marker Therapeutics is more favorable than Enveric Biosciences.
13.8% of Enveric Biosciences shares are held by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are held by institutional investors. 1.1% of Enveric Biosciences shares are held by insiders. Comparatively, 14.5% of Marker Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Enveric Biosciences has a net margin of 0.00% compared to Marker Therapeutics' net margin of -179.74%. Marker Therapeutics' return on equity of -89.63% beat Enveric Biosciences' return on equity.
Summary
Marker Therapeutics beats Enveric Biosciences on 15 of the 18 factors compared between the two stocks.
Get Enveric Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENVB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enveric Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:ENVB) was last updated on 5/21/2025 by MarketBeat.com Staff
Buy ENVB Stock Free ENVB Stock Alerts